Search Results - "Chu, Michael P"

An In Vitro Model for Acute Myeloid Leukemia Relapse Using the SORE6 Reporter by Lai, Justine, Shang, Chuquan, Chen, Will, Izevbaye, Iyare, Chu, Michael P, Sandhu, Irwindeep, Brandwein, Joseph, Lai, Raymond, Wang, Peng

“…Many patients diagnosed with acute myeloid leukemia (AML) relapse within two years of the initial remission. The biology of AML relapse is incompletely…”
Get full text

ULK2 Is a Key Pro-Autophagy Protein That Contributes to the High Chemoresistance and Disease Relapse in FLT3-Mutated Acute Myeloid Leukemia by Lai, Justine, Yang, Claire, Shang, Chuquan, Chen, Will, Chu, Michael P, Brandwein, Joseph, Lai, Raymond, Wang, Peng

“…We recently demonstrated that a small subset of cells in FLT3-mutated acute myeloid leukemia (AML) cell lines exhibit SORE6 reporter activity and cancer…”
Get full text

Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma by Chu, Michael P., Li, Yuetong, Ghosh, Sunita, Sass, Shelley, Smylie, Michael, Walker, John, Sawyer, Michael B.

“…Background Body composition is minimally investigated in an immunotherapy era. Specific body composition signals such as myosteatosis may reflect aspects of…”
Get full text

MS4A4A: a novel cell surface marker for M2 macrophages and plasma cells by Sanyal, Ratna, Polyak, Maria J, Zuccolo, Jonathan, Puri, Mandip, Deng, Lili, Roberts, Luc, Zuba, Ania, Storek, Jan, Luider, Joanne M, Sundberg, Ellen M, Mansoor, Adnan, Baigorri, Eva, Chu, Michael P, Belch, Andrew R, Pilarski, Linda M, Deans, Julie P

“…MS4A4A is a member of the membrane‐spanning, four domain family, subfamily A (MS4A) that includes CD20 (MS4A1), FcRβ (MS4A2) and Htm4 (MS4A3). Like the first…”
Get full text

Disease Characteristics and Outcomes of 493 Young Myeloma Patients Treated With Modern Therapies: A Canadian Myeloma Research Group Database Study by Tanguay, Mégane, Roy, Jean, Su, Jiandong, Gul, Engin, Reece, Donna, Venner, Christopher P., White, Darrell, Chu, Michael P., Jimenez‐Zepada, Victor H., Song, Kevin, Mccurdy, Arleigh, Mian, Hira, Sebag, Michael, Bergstrom, Debra, Stakiw, Julie, Reiman, Anthony, Kotb, Rami, Aslam, Muhammad, Kaedbey, Rayan, Louzada, Martha, LeBlanc, Richard

“…ABSTRACT Background Young patients ≤ 50 years old with multiple myeloma (MM) account for about 10% of cases and are underrepresented in the literature. Methods…”
Get full text

Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer by Wong, Grace G., Ha, Vincent, Chu, Michael P., Dersch-Mills, Deonne, Ghosh, Sunita, Chambers, Carole R., Sawyer, Michael B.

“…Proton pump inhibitors (PPIs) have been implicated in the impaired absorption of various oral oncologic therapies. Significantly reduced 3-year recurrence-free…”
Get full text

Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial by McCurdy, Arleigh, Reece, Donna, Louzada, Martha L., White, Darrell, Parkin, Stephen, Chu, Michael P., Kotb, Rami, Mian, Hira, Othman, Ibraheem, Su, Jiandong, Khan, Aniba, Gul, Engin, Trudel, Suzanne

“…Given the early use of triplet and quadruplet regimens, most patients with multiple myeloma (MM) will be exposed and/or refractory to PIs, IMiDs, and anti-CD38…”
Get full text

Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy by Chu, Michael P, Lieffers, Jessica, Ghosh, Sunita, Belch, Andrew R, Chua, Neil S, Fontaine, Amelie, Sangha, Randeep, Turner, A Robert, Baracos, Vickie E, Sawyer, Michael B

“…Skeletal muscle radio-density (SMD) measures muscle radiation attenuation (in Hounsfield Units, HU) on computed tomography (CT) scans. Low SMD is prognostic of…”
Get full text

Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics by Ogiya, Daisuke, Chyra, Zuzana, Verselis, Sigitas J., O’Keefe, Morgan, Cobb, Jacquelyn, Abiatari, Ivane, Talluri, Srikanth, Sithara, Anjana Anilkumar, Hideshima, Teru, Chu, Michael P., Hájek, Roman, Dorfman, David M., Pilarski, Linda M., Anderson, Kenneth C., Adamia, Sophia

“…Novel drug discoveries have shifted the treatment paradigms of most hematological malignancies, including multiple myeloma (MM). However, this plasma cell…”
Get full text

Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database by Côté, Julie, LeBlanc, Richard, Mian, Hira, Chu, Michael P., McCurdy, Arleigh, Masih-Khan, Esther, Su, Jiandong, Jimenez-Zepeda, Victor H., Song, Kevin, Louzada, Martha, White, Darrell, Sebag, Michael, Reiman, Anthony, Stakiw, Julie, Kotb, Rami, Bergstrom, Debra, Aslam, Muhammad, Kaedbey, Rayan, Venner, Christopher P., Gul, Engin, Reece, Donna

“…Autologous stem cell transplant (ASCT) remains an important option for eligible multiple myeloma (MM) patients as part of initial therapy. Using the Canadian…”
Get full text

Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model by Huang, Yung-Hsing, Molavi, Ommoleila, Alshareef, Abdulraheem, Haque, Moinul, Wang, Qian, Chu, Michael P, Venner, Christopher P, Sandhu, Irwindeep, Peters, Anthea C, Lavasanifar, Afsaneh, Lai, Raymond

“…Malignant cells cultured in three-dimensional (3D) models have been found to be phenotypically and biochemically different from their counterparts cultured…”
Get full text

Metabolic and inflammatory risk reduction in response to lipid-lowering and lifestyle modification in the medically underserved individuals by Chu, Michael P., Many, Gina, Isquith, Daniel A, McKeeth, Susan, Williamson, Jayne, Neradilek, Moni B, Colletti, Patrick, Zhao, Xue-Qiao

“…Medically underserved (US) populations have an increased level of atherosclerotic cardiovascular disease (ASCVD) risk, however, few studies investigated ASCVD…”
Get full text

Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial by Bahlis, Nizar J., Costello, Caitlin L., Raje, Noopur S., Levy, Moshe Y., Dholaria, Bhagirathbhai, Solh, Melhem, Tomasson, Michael H., Damore, Michael A., Jiang, Sibo, Basu, Cynthia, Skoura, Athanasia, Chan, Edward M., Trudel, Suzanne, Jakubowiak, Andrzej, Gasparetto, Cristina, Chu, Michael P., Dalovisio, Andrew, Sebag, Michael, Lesokhin, Alexander M.

“…Multiple myeloma (MM) is a plasma cell malignancy expressing B cell maturation antigen (BCMA). Elranatamab, a bispecific antibody, engages BCMA on MM and CD3…”
Get full text

Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial by Trudel, Suzanne, McCurdy, Arleigh, Louzada, Martha L., Parkin, Stephen, White, Darrell, Chu, Michael P., Kotb, Rami, Mian, Hira, Othman, Ibraheem, Su, Jiandong, Khan, Aniba, Gul, Engin, Reece, Donna

“…Due to evolving treatment standards for newly diagnosed multiple myeloma, many patients will be triple-class exposed after initial relapses and have poor…”
Get full text

Skeletal muscle density is an independent predictor of diffuse large B‐cell lymphoma outcomes treated with rituximab‐based chemoimmunotherapy by Chu, Michael P., Lieffers, Jessica, Ghosh, Sunita, Belch, Andrew, Chua, Neil S., Fontaine, Amelie, Sangha, Randeep, Turner, Robert A., Baracos, Vickie E., Sawyer, Michael B.

“…Background While much cancer research focuses on tumours and their microenvironment, malignancies cause widespread physiologic changes. Cancer and…”
Get full text

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial by Frank, Matthew J, Khodadoust, Michael S, Czerwinski, Debra K, Haabeth, Ole A W, Chu, Michael P, Miklos, David B, Advani, Ranjana H, Alizadeh, Ash A, Gupta, Neel K, Maeda, Lauren S, Reddy, Sunil A, Laport, Ginna G, Meyer, Everett H, Negrin, Robert S, Rezvani, Andrew R, Weng, Wen-Kai, Sheehan, Kevin, Faham, Malek, Okada, Ami, Moore, A Holliston, Phillips, Destiny L, Wapnir, Irene L, Brody, Joshua D, Levy, Ronald

“…Here, we report on the results of a phase I/II trial (NCT00490529) for patients with mantle cell lymphoma who, having achieved remission after…”
Get full text

Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer by Chu, Michael P, Ghosh, Sunita, Chambers, Carole R, Basappa, Naveen, Butts, Charles A, Chu, Quincy, Fenton, David, Joy, Anil A, Sangha, Randeep, Smylie, Michael, Sawyer, Michael B

“…Micro-Abstract Tyrosine kinase inhibitors (TKIs) are the focus in oncology research. As oral drugs, TKIs often have pH-dependent solubility—suggesting…”
Get full text

The cure of ageing: vitamin D—magic or myth? by Chu, Michael P, Alagiakrishnan, Kannayiram, Sadowski, Cheryl

“…Vitamin D was initially thought only to function in calcium homeostasis. However, it has multiple roles in human health, including neuromuscular and immune…”
Get full text

Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL by Katz, Deborah A., Morris, Joan D., Chu, Michael P., David, Kevin A., Thieblemont, Catherine, Morley, Nicholas J., Khan, Sharif S., Viardot, Andreas, Martín García-Sancho, Alejandro, Rodríguez-García, Guillermo, Bastos-Oreiro, Mariana, Lee, Seung Tae, Kormany, William, Chen, Yuqi, Wong, Hansen L., Anderson, Abraham A., Katlinskaya, Yuliya, Avilion, Ariel A., Dai, Tian, González-Barca, Eva

“…This open-label, multicenter, single-arm, phase 2 study assessed the safety and efficacy of blinatumomab consolidation therapy in adult patients with newly…”
Get full text

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial by Chu, Michael P, Hecht, J Randolph, Slamon, Dennis, Wainberg, Zev A, Bang, Yung-Jue, Hoff, Paulo M, Sobrero, Alberto, Qin, Shukui, Afenjar, Karen, Houe, Vincent, King, Karen, Koski, Sheryl, Mulder, Karen, Hiller, Julie Price, Scarfe, Andrew, Spratlin, Jennifer, Huang, Yingjie J, Khan-Wasti, Saba, Chua, Neil, Sawyer, Michael B

“…Capecitabine is an oral cytotoxic chemotherapeutic commonly used across cancer subtypes. As with other oral medications though, it may suffer from drug…”
Get more information